The three objectives of a study by Wolkin et al. (A-28) were to determine

(a) the effects of chronic haloperidol treatment on cerebral metabolism in schizophrenic patients,

(b) the relation between negative symptoms and haloperidol-induced regional changes in cerebral glucose utilization, and (c)

the relation between metabolic change and clinical antipsychotic effect. Subjects were 18 male veterans’ hospital inpatients (10 black, five white, and three Hispanic) with either acute or chronic decompensation of schizophrenia. Subjects ranged in age from 26 to 44 years, and their duration of illness ranged from 7 to 27 years. Among the data collected were the following pretreatment scores on the digit-symbol substitution subtest of the WAIS-R (DSY1RW) and haloperidol-induced change in absolute left dorsolateral prefrontal cortex (DLLA3V1) and absolute right dorsolateral prefrontal cortex (DLRA3V1) measured in units of mmol glucose/100 g tissue/min:

DSY1RW DLLA3V1 DLRA3V1 DSY1RW DLLA3V1 DLRA3V1 47 7:97 17:17 18 4:91 9:58 16 8:08 9:59 0 1:71 .40 31 10:15 11:58 29 4:62 4:57 34 5:46 2:16 17 9.48 11.31 22 17:12 12:95 38 6:59 6:47 70 12:12 13:01 64 12:19 13:61 59 9:70 12:61 52 15:13 11:81 41 9:02 7:48 50 10:82 9:45 0 4.67 7.26 62 4:92 1:87 Source: Data provided courtesy of Dr. Adam Wolkin.